Cardiotoxicity of doxorubicin: Causes, diagnosis, consequences and possibilities of prevention

Introduction: Doxorubicin is an antibiotic from the anthracycline group, with clinical use limited by adverse reactions, primarily cardiotoxicity. Material and Methods: This article provides an overview of therapeutic and toxic doses of doxorubicin, the mechanism of side effects, markers for early d...

Full description

Bibliographic Details
Main Authors: Radić Jelena P., Kolarov Bjelobrk Ivana N., Stefanović Maja Z., Bosanac Milana M., Cvetković Biljana R., Janičić Stefan D., Dolamić Borislav E., Ćuk Dragomir R., Andrejić-Višnjić Bojana M.
Format: Article
Language:English
Published: Srpsko lekarsko drustvo 2022-01-01
Series:Hospital Pharmacology
Subjects:
Online Access:https://scindeks-clanci.ceon.rs/data/pdf/2334-9492/2022/2334-94922201143R.pdf
_version_ 1811231915368251392
author Radić Jelena P.
Kolarov Bjelobrk Ivana N.
Stefanović Maja Z.
Bosanac Milana M.
Cvetković Biljana R.
Janičić Stefan D.
Dolamić Borislav E.
Ćuk Dragomir R.
Andrejić-Višnjić Bojana M.
author_facet Radić Jelena P.
Kolarov Bjelobrk Ivana N.
Stefanović Maja Z.
Bosanac Milana M.
Cvetković Biljana R.
Janičić Stefan D.
Dolamić Borislav E.
Ćuk Dragomir R.
Andrejić-Višnjić Bojana M.
author_sort Radić Jelena P.
collection DOAJ
description Introduction: Doxorubicin is an antibiotic from the anthracycline group, with clinical use limited by adverse reactions, primarily cardiotoxicity. Material and Methods: This article provides an overview of therapeutic and toxic doses of doxorubicin, the mechanism of side effects, markers for early detection as well as currently available preparations for preventing its toxicity. We searched PubMed, Google Scholar, SCIndex, Dimension, Scopus and Google for English and Serbian language abstracts, using the searching terms "doxorubicin", "cardiotoxicty", "carotenoids", "oncology", "oxidative stress", "DNA damage" and "biomarkers". Topic: The mechanism of side effects is still unclear and is considered to be multifactorial including ROS overproduction, reducing levels of endogenous antioxidants, DNA damage, large drug accumulation in cardiac tissue, calcium overload, histamine release, and impairment of autoimmune regulation of cardiac function Manifestations of cardiotoxicity are mainly acute (appear inside 24h atypical changes of ST segment, decrease in QRS complex voltage, tachycardia and supraventricular extrasystoles are observed, but can also be subacute and chronic (cardiomyocyte edema, disorganzation, fibroblast proliferation, necrosis). Diagnosis of cardiotoxicity is based on ECG, ECHO, and biochemical markers, among which the most important are troponins, while pathohistological verification is necessary for the final diagnosis. Some medications (carvedilol, atorvastatin) have showed some level of cardioprotection against DOX, but there is no overall agreement on their administration solely for this purpose. An increasing number of studies have tested various dietary supplements and natural preparations (already in the human diet) in order to discover those that could completely prevent or reduce the toxic effects of doxorubicin, with special focus on carotenoids. Conclusion: Cardiotoxicity is the leading side effect of doxorubicin, and therefore there is an active search for either new biomarkers and/or diagnostic protocols that would detect toxicity in time, as well as substances able to prevent the occurrence or alleviate DOXinduced cardiotoxicity.
first_indexed 2024-04-12T10:54:02Z
format Article
id doaj.art-3327787c03eb48bf9b5923a1c314b668
institution Directory Open Access Journal
issn 2334-9492
language English
last_indexed 2024-04-12T10:54:02Z
publishDate 2022-01-01
publisher Srpsko lekarsko drustvo
record_format Article
series Hospital Pharmacology
spelling doaj.art-3327787c03eb48bf9b5923a1c314b6682022-12-22T03:36:08ZengSrpsko lekarsko drustvoHospital Pharmacology2334-94922022-01-01911143115110.5937/hpimj2201143R2334-94922201143RCardiotoxicity of doxorubicin: Causes, diagnosis, consequences and possibilities of preventionRadić Jelena P.0Kolarov Bjelobrk Ivana N.1Stefanović Maja Z.2Bosanac Milana M.3Cvetković Biljana R.4Janičić Stefan D.5Dolamić Borislav E.6Ćuk Dragomir R.7Andrejić-Višnjić Bojana M.8https://orcid.org/0000-0001-6810-9190Oncology Institute of Vojvodina, Sremska Kamenica, SerbiaOncology Institute of Vojvodina, Sremska Kamenica, SerbiaUniversity of Novi Sad, Faculty of Medicine, Department of Emergency Medicine, SerbiaUniversity of Novi Sad, Faculty of Medicine, SerbiaUniversity of Novi Sad, Institute of food technology, SerbiaUniversity of Novi Sad, Faculty of Medicine, Department of Emergency Medicine, SerbiaCommunity health centre, Service for specialist-consultative activity, Novi Sad, SerbiaClinical center of Vojvodina, Center for Pathology and Histology, Novi Sad, SerbiaUniversity of Novi Sad, Faculty of Medicine, Department of histology and embryology, SerbiaIntroduction: Doxorubicin is an antibiotic from the anthracycline group, with clinical use limited by adverse reactions, primarily cardiotoxicity. Material and Methods: This article provides an overview of therapeutic and toxic doses of doxorubicin, the mechanism of side effects, markers for early detection as well as currently available preparations for preventing its toxicity. We searched PubMed, Google Scholar, SCIndex, Dimension, Scopus and Google for English and Serbian language abstracts, using the searching terms "doxorubicin", "cardiotoxicty", "carotenoids", "oncology", "oxidative stress", "DNA damage" and "biomarkers". Topic: The mechanism of side effects is still unclear and is considered to be multifactorial including ROS overproduction, reducing levels of endogenous antioxidants, DNA damage, large drug accumulation in cardiac tissue, calcium overload, histamine release, and impairment of autoimmune regulation of cardiac function Manifestations of cardiotoxicity are mainly acute (appear inside 24h atypical changes of ST segment, decrease in QRS complex voltage, tachycardia and supraventricular extrasystoles are observed, but can also be subacute and chronic (cardiomyocyte edema, disorganzation, fibroblast proliferation, necrosis). Diagnosis of cardiotoxicity is based on ECG, ECHO, and biochemical markers, among which the most important are troponins, while pathohistological verification is necessary for the final diagnosis. Some medications (carvedilol, atorvastatin) have showed some level of cardioprotection against DOX, but there is no overall agreement on their administration solely for this purpose. An increasing number of studies have tested various dietary supplements and natural preparations (already in the human diet) in order to discover those that could completely prevent or reduce the toxic effects of doxorubicin, with special focus on carotenoids. Conclusion: Cardiotoxicity is the leading side effect of doxorubicin, and therefore there is an active search for either new biomarkers and/or diagnostic protocols that would detect toxicity in time, as well as substances able to prevent the occurrence or alleviate DOXinduced cardiotoxicity.https://scindeks-clanci.ceon.rs/data/pdf/2334-9492/2022/2334-94922201143R.pdfdoxorubicincardiotoxicityoncologyside effects
spellingShingle Radić Jelena P.
Kolarov Bjelobrk Ivana N.
Stefanović Maja Z.
Bosanac Milana M.
Cvetković Biljana R.
Janičić Stefan D.
Dolamić Borislav E.
Ćuk Dragomir R.
Andrejić-Višnjić Bojana M.
Cardiotoxicity of doxorubicin: Causes, diagnosis, consequences and possibilities of prevention
Hospital Pharmacology
doxorubicin
cardiotoxicity
oncology
side effects
title Cardiotoxicity of doxorubicin: Causes, diagnosis, consequences and possibilities of prevention
title_full Cardiotoxicity of doxorubicin: Causes, diagnosis, consequences and possibilities of prevention
title_fullStr Cardiotoxicity of doxorubicin: Causes, diagnosis, consequences and possibilities of prevention
title_full_unstemmed Cardiotoxicity of doxorubicin: Causes, diagnosis, consequences and possibilities of prevention
title_short Cardiotoxicity of doxorubicin: Causes, diagnosis, consequences and possibilities of prevention
title_sort cardiotoxicity of doxorubicin causes diagnosis consequences and possibilities of prevention
topic doxorubicin
cardiotoxicity
oncology
side effects
url https://scindeks-clanci.ceon.rs/data/pdf/2334-9492/2022/2334-94922201143R.pdf
work_keys_str_mv AT radicjelenap cardiotoxicityofdoxorubicincausesdiagnosisconsequencesandpossibilitiesofprevention
AT kolarovbjelobrkivanan cardiotoxicityofdoxorubicincausesdiagnosisconsequencesandpossibilitiesofprevention
AT stefanovicmajaz cardiotoxicityofdoxorubicincausesdiagnosisconsequencesandpossibilitiesofprevention
AT bosanacmilanam cardiotoxicityofdoxorubicincausesdiagnosisconsequencesandpossibilitiesofprevention
AT cvetkovicbiljanar cardiotoxicityofdoxorubicincausesdiagnosisconsequencesandpossibilitiesofprevention
AT janicicstefand cardiotoxicityofdoxorubicincausesdiagnosisconsequencesandpossibilitiesofprevention
AT dolamicborislave cardiotoxicityofdoxorubicincausesdiagnosisconsequencesandpossibilitiesofprevention
AT cukdragomirr cardiotoxicityofdoxorubicincausesdiagnosisconsequencesandpossibilitiesofprevention
AT andrejicvisnjicbojanam cardiotoxicityofdoxorubicincausesdiagnosisconsequencesandpossibilitiesofprevention